Thu, May 19, 2022 | By Cryoport Team
At Cryoport Systems, we are continuously striving to align with the latest science and technology advancements in our products and services, integrating the most advanced packaging, informatics, and...
Fri, Feb 11, 2022 | By Quin Waddell, Director of Monitoring Solutions
The future for global advanced therapy shipments requiring critical near real-time chain of custody, chain of condition and Chain of Compliance® reporting will soon face a significant technology...
Wed, Dec 15, 2021 | By Donna Thresher, Director of Global Regulatory Trade and Compliance, Cryoport Systems
Update: President Biden signed Proclamation 10326 To Modify the Harmonized Tariff Schedule of the United States and for Other Purposes on December 23rd, 2021. Thus, Customs and Border Protection...
Mon, Dec 06, 2021 | By Dave Wilson, Vice President EMEA
Biotech companies continue to innovate cutting-edge therapeutics, and the companies that support their efforts continue to strive for best practices as these new therapies advance and evolve. In the...
Tue, Nov 16, 2021 | By Rob Jones, Vice President of Global BioServices
Cryoport Systems is making significant progress since the last update on launching our Global BioServices in Houston, Texas and Morris Plains, New Jersey. These two prime locations were chosen...
Mon, Sep 20, 2021 | By Gregory Stevens, Executive Director - Business Operations
Are you experiencing the following 10 problems with your current logistics courier?
Wed, Sep 08, 2021 | By Rob Jones, Vice President of Global BioServices
One of the challenges facing the cell and gene therapy industry, as it grows and matures, is the development of robust supply chains to support the increase in clinical trials and the...
Thu, Jul 22, 2021 | By Cryoport Team
We’re celebrating big news from one of Cryoport Systems valued clients, bluebird bio! bluebird bio announced EU approval of their gene therapy Skysona™ for patients with Early Cerebral...
Fri, Feb 12, 2021 | By Cryoport Team
While the pandemic continues to disrupt many industries, including regenerative medicine, it’s not all bad news -- in fact, there are likely some bright spots ahead for the industry this year.
Mon, Jan 11, 2021 | By Cryoport Team
2020 was an incredible year of growth for Cryoport, Inc. The acquisitions of CRYOPDP and MVE Biological Solutions dramatically increased our global network and capabilities, and we achieved a new...
Mon, Dec 28, 2020 | By Donna Thresher, Director of Global Regulatory Trade and Compliance, Cryoport Systems
On January 31, 2020, the United Kingdom (UK) officially withdrew from the European Union (EU). An eleven-month transition period was enacted to negotiate trade terms between...
Wed, Dec 02, 2020 | By Donna Thresher, Director of Global Regulatory Trade and Compliance, Cryoport Systems
The Brexit transition period is set to expire on December 31, 2020. If you have questions regarding possible outcomes and effects on transporting goods across international borders, please review the...
Mon, Nov 30, 2020 | By Ryan Carpentier, Global Vice President -- Business Development, Cryoport Systems
The events of 2020 put unprecedented pressures on the pharmaceutical and logistics industries. As the pandemic lobbed one challenge after the next – cancelled flights, limited flight cargo space,...
Mon, Nov 16, 2020 | By Rob Jones, Vice President of Global BioServices
You may have heard about the release of ISO 21973:2020, but are wondering what it means. Our experts are here to break it down for you.
Mon, Nov 16, 2020 | By Cryoport Team
As we approach the annual flu season, Cryoport continues its efforts to proactively monitor the global resurgence of the COVID-19 virus. Cryoport has doubled its efforts to ensure continuity of...
Tue, Oct 20, 2020 | By Adam Fox, Vice President - Quality Assurance & Regulatory Affairs
Cell and gene therapies may be considered novel by the general public today, but they are on the path to dramatically improve the lives of those with chronic conditions and cancers. While a handful...
Mon, Oct 05, 2020 | By Michael Dybicz, Vice President - Consulting Services
Biopharmaceutical supply chains are among the most complex and costly processes on the planet. CAR T-cell therapies, which can cost hundreds of thousands of dollars to create, can be rendered...
Tue, Sep 01, 2020 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport
Cryoport made two bold moves in the last couple of weeks to further our ability to support the growing number of clinical trials and the coming wave of global commercially approved therapies in the...
Tue, Aug 11, 2020 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport
Cryoport recently marked some significant milestones. We are now supporting four commercial biopharma therapies, and a fifth's commercial submission was recently validated by the European Medicines...
Wed, Jun 24, 2020 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain
The last few months have been unprecedented in world history. The pandemic that is gripping the world has spared no country, culture or corner, and it has highlighted the gaps in many companies’...
Tue, Apr 14, 2020 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport
As the world experiences unprecedented times caused by the COVID-19 pandemic, Cryoport has been collaborating closely with our clients to help navigate this dynamic environment and to ensure ...
Thu, Feb 06, 2020 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain
Recently the FDA’s Center for Biologics Evaluation and Research issued its guidance to the regenerative medicine industry on best practices for submitting an IND application to the FDA for gene...
Fri, Dec 06, 2019 | By Cryoport Team
New became the norm at Cryoport this year. The company announced new partnerships, new product lines, and new services seemingly every week. On top of these exciting developments were notable...
Thu, Nov 21, 2019 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain
There is no question that the groundbreaking treatments being developed in Cell & Gene Therapy (CGT) are fundamentally changing the way patient care is managed around the world. As with most...
Americas • EMEA • APAC
Sales • +1 949.232.1900 | Support • +1 949.470.2300
©2021 Cryoport Systems, LLC. All rights reserved.
A Leap Forward in Standardizing the Regenerative Medicine Supply Chain – What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC
